MiNK Therapeutics reported Q3 2025 results, highlighting durable clinical responses with agenT-797 and strategic expansion of its iNKT platform. The company strengthened its leadership team and extended its cash runway through 2026, positioning it for pivotal development.
Updated clinical data showed sustained tumor regression and immune reprogramming with agenT-797, including complete remissions lasting over two years in refractory cancers.
positiveThe company initiated a preclinical and Phase 1 study of agenT-797 for GvHD prevention and relapse reduction, supported by non-dilutive funding from NIH and philanthropic grants.
positiveCash position of approximately $14.3 million at the end of Q3 2025, with an additional $1.2 million raised, extending the expected cash runway through 2026.
positiveStrengthened leadership with the addition of Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases and Colonel (Ret.) John B. Holcomb, MD, FACS to the Board of Directors.
neutralNet loss for Q3 2025 was $2.9 million, an increase from $1.8 million in Q3 2024, reflecting ongoing R&D activities.
negativeNet loss for the nine-month period ended Q3 2025 was $9.9 million, an increase from $8.3 million in the prior year period.
negativeMargin metrics will be available once backend extracts data from insights_json
MiNK Therapeutics is advancing toward pivotal development across oncology, pulmonary disease, and transplantation with its iNKT platform.
The company's lead asset, agenT-797, has shown durable clinical responses and a favorable safety profile.
Strategic expansion into new disease areas like GvHD and severe pulmonary disease is supported by non-dilutive funding.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.